Novo Nordisk Q1 Results Exceed Expectations Amidst Competitive Pressure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 38 minutes ago
0mins
Should l Buy LLY?
Source: Newsfilter
- Strong Performance: Novo Nordisk reported an adjusted operating profit of 32.86 billion Danish crowns ($5.16 billion) in Q1, surpassing the market expectation of 28.74 billion crowns, indicating robust demand for its weight-loss drug amid fierce competition.
- Sales Outlook Adjustment: The company now expects adjusted sales and operating profit to decline by 4% to 12% this year, an improvement from the previous forecast of a 5% to 13% decline, reflecting sustained demand for its new Wegovy pill.
- Intensifying Market Competition: With Eli Lilly's competing drug Foundayo receiving FDA approval, Novo Nordisk's exclusive position in the U.S. market has been threatened, necessitating more aggressive pricing and market share strategies.
- Stock Price Volatility: Novo Nordisk's stock has fallen nearly 40% over the past 12 months, while Eli Lilly's shares have risen about 18%, although Novo's stock has shown signs of recovery since late March, reflecting optimistic market sentiment towards its weight-loss pill.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 967.930
Low
950.00
Averages
1192
High
1500
Current: 967.930
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
Novo Nordisk Raises 2026 Profit Guidance Amid Strong Wegovy Sales
- Sales Surge: Novo Nordisk reported a 32% year-on-year increase in first-quarter sales to 96.8 billion Danish kroner ($15.2 billion), significantly exceeding analyst expectations of 71.3 billion kroner, indicating robust demand for its weight-loss drugs and reinforcing its leadership in the obesity treatment market.
- Profit Boost: Operating profit soared 65% year-on-year to 59.6 billion kroner, greatly surpassing market expectations of 31.7 billion kroner, reflecting successful strategies in cost control and market expansion, which bolstered investor confidence.
- New Drug Highlights: The oral weight-loss drug Wegovy generated sales of 2.26 billion kroner in the U.S., well above analyst estimates of 1.16 billion kroner, marking a strong market entry that could reshape competitive dynamics in the weight-loss sector.
- Optimistic Market Outlook: The company raised its 2026 full-year profit guidance based on increased expectations for GLP-1 product sales, now forecasting adjusted sales to contract by 4% to 12%, demonstrating confidence in future market demand despite intense competitive pressures.
See More
Novo Nordisk Q1 Results Exceed Expectations Amidst Competitive Pressure
- Strong Performance: Novo Nordisk reported an adjusted operating profit of 32.86 billion Danish crowns ($5.16 billion) in Q1, surpassing the market expectation of 28.74 billion crowns, indicating robust demand for its weight-loss drug amid fierce competition.
- Sales Outlook Adjustment: The company now expects adjusted sales and operating profit to decline by 4% to 12% this year, an improvement from the previous forecast of a 5% to 13% decline, reflecting sustained demand for its new Wegovy pill.
- Intensifying Market Competition: With Eli Lilly's competing drug Foundayo receiving FDA approval, Novo Nordisk's exclusive position in the U.S. market has been threatened, necessitating more aggressive pricing and market share strategies.
- Stock Price Volatility: Novo Nordisk's stock has fallen nearly 40% over the past 12 months, while Eli Lilly's shares have risen about 18%, although Novo's stock has shown signs of recovery since late March, reflecting optimistic market sentiment towards its weight-loss pill.
See More
Viking Therapeutics Accelerates Obesity Drug Development
- Clinical Trial Progress: Viking Therapeutics has fully enrolled both late-stage Vanquish studies ahead of schedule, with over 4,500 and 1,000 patients respectively, indicating the company's proactive positioning in the obesity drug market despite pressure from competitors like Pfizer.
- Financial Challenges: The company reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the previous year, while R&D expenses surged to $150.2 million, reflecting high investment in obesity drug development.
- Intensifying Market Competition: Pfizer highlighted obesity drugs as a major future growth driver in its latest earnings report, anticipating that its $10 billion Metsera deal will lead to strong growth post-2028, thereby intensifying competition in the obesity drug market.
- Investor Sentiment: Despite financial pressures, VKTX maintains an 'extremely bullish' sentiment among retail investors, with a 700% surge in message volume over 24 hours, indicating strong market confidence in its obesity drug VK2735.
See More
Market Update: Corporate Earnings and Oil Price Impact
- DuPont Earnings Beat: DuPont reported better-than-expected earnings, with strong performance in healthcare, aerospace, and automotive sectors, although disruptions in the Middle East affected its water market; the organic sales guidance for the year was raised to 4%, indicating resilience against cost pressures, leading to a 2% increase in shares this morning.
- Eaton's Mixed Results: Eaton posted earnings and revenue beats, but shares fell approximately 4.5% due to conservative guidance and a miss in Electrical Americas; however, accelerating sales and order growth, along with backlog increases, suggest underlying strength, making the upcoming earnings call crucial for investor sentiment.
- Amazon Supply Chain Expansion: Amazon announced it would open its supply chain network to other companies, attracting major clients like Procter & Gamble, American Eagle, and 3M, which underscores its ambitions across retail, logistics, and health sectors, further solidifying its market position.
- Norwegian Cruise Line Guidance Cut: Norwegian Cruise Line issued a larger-than-expected guidance cut due to soft pricing, attributing below-optimal bookings to execution issues exacerbated by the Middle East conflict, prompting Goldman Sachs to lower its price target from $18 to $14, reflecting market concerns about its future performance.
See More
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
Novo Nordisk Raises 2026 Profit Guidance Amid Strong Wegovy Sales
- Sales Surge: Novo Nordisk reported a 32% year-on-year increase in first-quarter sales to 96.8 billion Danish kroner ($15.2 billion), significantly exceeding analyst expectations of 71.3 billion kroner, indicating robust demand for its weight-loss drugs and reinforcing its leadership in the obesity treatment market.
- Profit Boost: Operating profit soared 65% year-on-year to 59.6 billion kroner, greatly surpassing market expectations of 31.7 billion kroner, reflecting successful strategies in cost control and market expansion, which bolstered investor confidence.
- New Drug Highlights: The oral weight-loss drug Wegovy generated sales of 2.26 billion kroner in the U.S., well above analyst estimates of 1.16 billion kroner, marking a strong market entry that could reshape competitive dynamics in the weight-loss sector.
- Optimistic Market Outlook: The company raised its 2026 full-year profit guidance based on increased expectations for GLP-1 product sales, now forecasting adjusted sales to contract by 4% to 12%, demonstrating confidence in future market demand despite intense competitive pressures.
See More
Novo Nordisk Q1 Results Exceed Expectations Amidst Competitive Pressure
- Strong Performance: Novo Nordisk reported an adjusted operating profit of 32.86 billion Danish crowns ($5.16 billion) in Q1, surpassing the market expectation of 28.74 billion crowns, indicating robust demand for its weight-loss drug amid fierce competition.
- Sales Outlook Adjustment: The company now expects adjusted sales and operating profit to decline by 4% to 12% this year, an improvement from the previous forecast of a 5% to 13% decline, reflecting sustained demand for its new Wegovy pill.
- Intensifying Market Competition: With Eli Lilly's competing drug Foundayo receiving FDA approval, Novo Nordisk's exclusive position in the U.S. market has been threatened, necessitating more aggressive pricing and market share strategies.
- Stock Price Volatility: Novo Nordisk's stock has fallen nearly 40% over the past 12 months, while Eli Lilly's shares have risen about 18%, although Novo's stock has shown signs of recovery since late March, reflecting optimistic market sentiment towards its weight-loss pill.
See More
Viking Therapeutics Accelerates Obesity Drug Development
- Clinical Trial Progress: Viking Therapeutics has fully enrolled both late-stage Vanquish studies ahead of schedule, with over 4,500 and 1,000 patients respectively, indicating the company's proactive positioning in the obesity drug market despite pressure from competitors like Pfizer.
- Financial Challenges: The company reported a Q1 net loss of $158.3 million, or $1.37 per share, which is more than triple the $45.6 million loss from the previous year, while R&D expenses surged to $150.2 million, reflecting high investment in obesity drug development.
- Intensifying Market Competition: Pfizer highlighted obesity drugs as a major future growth driver in its latest earnings report, anticipating that its $10 billion Metsera deal will lead to strong growth post-2028, thereby intensifying competition in the obesity drug market.
- Investor Sentiment: Despite financial pressures, VKTX maintains an 'extremely bullish' sentiment among retail investors, with a 700% surge in message volume over 24 hours, indicating strong market confidence in its obesity drug VK2735.
See More
Market Update: Corporate Earnings and Oil Price Impact
- DuPont Earnings Beat: DuPont reported better-than-expected earnings, with strong performance in healthcare, aerospace, and automotive sectors, although disruptions in the Middle East affected its water market; the organic sales guidance for the year was raised to 4%, indicating resilience against cost pressures, leading to a 2% increase in shares this morning.
- Eaton's Mixed Results: Eaton posted earnings and revenue beats, but shares fell approximately 4.5% due to conservative guidance and a miss in Electrical Americas; however, accelerating sales and order growth, along with backlog increases, suggest underlying strength, making the upcoming earnings call crucial for investor sentiment.
- Amazon Supply Chain Expansion: Amazon announced it would open its supply chain network to other companies, attracting major clients like Procter & Gamble, American Eagle, and 3M, which underscores its ambitions across retail, logistics, and health sectors, further solidifying its market position.
- Norwegian Cruise Line Guidance Cut: Norwegian Cruise Line issued a larger-than-expected guidance cut due to soft pricing, attributing below-optimal bookings to execution issues exacerbated by the Middle East conflict, prompting Goldman Sachs to lower its price target from $18 to $14, reflecting market concerns about its future performance.
See More
